The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (TRIP) compound with an effective amount of the therapeutic agent. In particular embodiments, the TRIP compound enhances the immune response of the subject to the therapeutic agent. In some embodiments, the TRIP compound is administered in different dosing schedules to provide a biphasic immunomodulation effect.

The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.

The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.

Primarily aimed at providing a novel pharmaceutical composition. The present invention relates to a pharmaceutical composition that contains a cerium compound as an active ingredient.

Primarily aimed at providing a novel pharmaceutical composition. The present invention relates to a pharmaceutical composition that contains a cerium compound as an active ingredient.

A dispersion solution contains a complex of cerium oxide nanoparticle with protein in which a hydrodynamic diameter and zeta potential of the protein are maintained. The dispersion solution is produced by mixing a solution containing the protein with a solution containing a cerium (III) ion or with a cerium (III) salt followed by adding an oxidizing agent thereto.

A dispersion solution contains a complex of cerium oxide nanoparticle with protein in which a hydrodynamic diameter and zeta potential of the protein are maintained. The dispersion solution is produced by mixing a solution containing the protein with a solution containing a cerium (III) ion or with a cerium (III) salt followed by adding an oxidizing agent thereto.

Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

The disclosure provides, inter alia, compositions including cell-nanoparticle constructs and drug loaded nanoparticles, and methods for their use in the treatment of cancer. Also provided are unmodified cisplatin molecules encapsulated by silica nanoparticles, and their use in the treatment of cancer.

Described is an initial liquid composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising chelated metal oxide particles suspended in a polyol, such that metal oxide particles are homogeneously dispersed in a primarily liquid based polyol carrier so that chelated metal oxide particles form a stable complex suspension that is optionally an alkaline based aqueous silver oxide dispersion. The liquid composition can be subsequently added to any polymer or polymer compound/system where the polymer degrades or melts at a temperature lower than the polyol carrier degradation or boiling temperature. The metal oxide complex may also impart beneficial semi-conductive or conductive as well as permeability and flammability property changes to the polymer (host) system.